(Q39985088)

16 September 2017

title

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism (English)

1 reference

16 September 2017

0 references

1 reference

2

1 reference

16 September 2017

3

1 reference

16 September 2017

6

1 reference

16 September 2017

5

Ruggero De Maria

1 reference

16 September 2017

Gustavo Ortiz-Ferrón

1

1 reference

16 September 2017

Ana I López-Pérez

series ordinal

4

1 reference

16 September 2017

publication date

1 June 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

18

1 reference

16 September 2017

issue

6

1 reference

16 September 2017

page(s)

664-676

1 reference

https://scigraph.springernature.com/pub.10.1038/cr.2008.54

16 September 2017

exact match

0 references

cites work

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Direct repression of the Mcl-1 promoter by E2F1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Promoting apoptosis as a strategy for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Potential and caveats of TRAIL in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Role of acidic sphingomyelinase in Fas/CD95-mediated cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

7 January 2021

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

7 January 2021

Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

7 January 2021

TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCR.2008.54

7 January 2021

Identifiers

DOI

10.1038/CR.2008.54

1 reference

16 September 2017

1 reference